These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1149 related articles for article (PubMed ID: 16753135)
1. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135 [TBL] [Abstract][Full Text] [Related]
2. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094 [TBL] [Abstract][Full Text] [Related]
3. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279 [TBL] [Abstract][Full Text] [Related]
4. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419 [TBL] [Abstract][Full Text] [Related]
6. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR; Shankar S; Chen X; Asim M; Srivastava RK Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373 [TBL] [Abstract][Full Text] [Related]
8. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639 [TBL] [Abstract][Full Text] [Related]
9. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
10. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Chen X; Kandasamy K; Srivastava RK Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723 [TBL] [Abstract][Full Text] [Related]
11. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Suliman A; Lam A; Datta R; Srivastava RK Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196 [TBL] [Abstract][Full Text] [Related]
13. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Kazhdan I; Marciniak RA Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201 [TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Cuello M; Ettenberg SA; Nau MM; Lipkowitz S Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126 [TBL] [Abstract][Full Text] [Related]
15. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Abdollahi T; Robertson NM; Abdollahi A; Litwack G Cancer Res; 2003 Aug; 63(15):4521-6. PubMed ID: 12907626 [TBL] [Abstract][Full Text] [Related]
16. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Liu X; Yue P; Khuri FR; Sun SY Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375 [TBL] [Abstract][Full Text] [Related]
17. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP; Zisman A; Bonavida B Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140 [TBL] [Abstract][Full Text] [Related]
18. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632 [TBL] [Abstract][Full Text] [Related]
19. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts. Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284 [TBL] [Abstract][Full Text] [Related]
20. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Kang J; Bu J; Hao Y; Chen F Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]